Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Dose Escalation Study To Evaluate the Safety and Biologically Effective Dose of GEO-CM04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers

NCT04639466 is registered in ClinicalTrials.gov with GeoVax, Inc. as lead sponsor.

NCT NCT04639466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04639466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Dose Escalation Study To Evaluate the Safety and Biologically Effective Dose of GEO-CM04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers
Lead sponsor
GeoVax, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 19, 2020
Completion date
December 3, 2025
Enrollment
119 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection